CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income	$ 128,291	$ 59,926	$ 21,411
Adjustments to reconcile net income to net cash provided by operating activities:
Inventory step-up charges	2,130	734	1,483
Depreciation and amortization	38,447	27,067	20,868
Amortization of debt discount and issuance costs	11,530	10,970	7,536
Stock-based compensation expense	27,500	17,007	12,847
Contingent consideration expense	5,865
Deferred income taxes, net	6,517	(3,992)	(624)
Loss on conversion of debt	13		5,650
Other	851	267	663
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(46,523)	(20,892)	(7,830)
Unbilled receivables	(2)	456	2,146
Inventories	(89,781)	(29,994)	(10,797)
Prepaid expenses and other assets	(10,192)	(4,870)	(595)
Operating lease right of use assets	(4,315)	3,583	(4,662)
Other assets	432	(281)	(66)
Accounts payable	19,523	2,462	662
Accrued expenses	23,196	1,037	13,096
Operating lease liability	6,958	(1,964)	5,447
Long-term liabilities	(1,424)	1,109	(19)
Total cash provided by operating activities	119,016	62,625	67,216
Cash flows from investing activities:
Additions to capitalized software costs	(4,187)	(3,889)	(4,650)
Acquisition of assets, net of cash acquired	(149,893)	(175,041)	(182,154)
Purchases of property, plant and equipment	(67,089)	(22,455)	(18,504)
Total cash used in investing activities	(221,169)	(201,385)	(205,308)
Cash flows from financing activities:
Proceeds from issuance of senior convertible notes, net of issuance costs			278,466
Proceeds from issuance of common stock, net of issuance costs		297,775	320,713
Exercise of stock options	3,879	8,151	1,167
Repayment of senior convertible notes	(21)		(114,989)
Payment of tax withholding obligation on vesting of restricted stock	(2,897)	(10)	(490)
Total cash provided by financing activities	961	305,916	484,867
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(12,286)	12,729	(3,190)
Net (decrease) increase in cash, cash equivalents and restricted cash	(113,478)	179,885	343,585
Cash, cash equivalents and restricted cash, beginning of period	717,292	537,407	193,822
Cash, cash equivalents and restricted cash, end of period	603,814	717,292	537,407
Supplemental disclosure of cash flow information:
Income taxes paid	16,515	10,279	6,505
Interest paid	1,066	1,066	1,484
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	85,312	3,349	8,663
Fair value of 2,316,229 shares of common stock issued for conversion of convertible notes			198,757
C Technologies Inc
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition			53,938
ARTeSYN Biosolutions Holdings Ireland Limited
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition		69,422
Avitide Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition	82,968	0	0
Fair value of earnouts related to acquisition	$ 94,238	$ 0	$ 0